

**WYETH PHARMACEUTICALS**  
**WORLDWIDE NET REVENUE BY PRODUCTS**  
**TWELVE MONTHS ENDED DECEMBER 31, 2002**  
**(000'S)**

	DOMESTIC				FOREIGN				TOTAL			
	YTD 2002	YTD 2001	DOLLAR CHANGE	PERCENT CHANGE	YTD 2002	YTD 2001	DOLLAR CHANGE	PERCENT CHANGE	YTD 2002	YTD 2001	DOLLAR CHANGE	PERCENT CHANGE
<b>EFFEXOR</b>	\$ 1,449,975	\$ 1,097,515	\$ 352,460	32.1%	\$ 622,341	\$ 444,501	\$ 177,840	40.0%	\$ 2,072,316	\$ 1,542,016	\$ 530,300	34.4%
<b>PREMARIN FAMILY</b>	1,613,842	1,795,558	(181,716)	-10.1%	266,018	277,967	(\$11,949)	-4.3%	1,879,860	2,073,525	(193,665)	-9.3%
<b>PROTONIX</b>	1,070,804	561,261	509,543	90.8%	-	-	-	NA	1,070,804	561,261	509,543	90.8%
<b>NUTRITIONALS</b>	47,672	46,451	1,221	2.6%	787,053	777,085	9,968	1.3%	834,725	823,536	11,189	1.4%
<b>PREVNAR</b>	572,969	767,479	(194,510)	-25.3%	74,559	30,731	43,828	142.6%	647,528	798,210	(150,682)	-18.9%
<b>ORAL CONTRACEPTIVES</b>	180,278	306,744	(126,466)	-41.2%	396,021	396,668	(647)	-0.2%	576,299	703,412	(127,113)	-18.1%
<b>ZOSYN/TAZOCIN</b>	208,247	240,252	(32,005)	-13.3%	197,832	199,555	(1,723)	-0.9%	406,079	439,807	(33,728)	-7.7%
<b>ZOTON</b>	-	-	-	NA	309,404	284,061	25,343	8.9%	309,404	284,061	25,343	8.9%
<b>CORDARONE</b>	279,496	265,058	14,438	5.4%	3,708	4,545	(837)	-18.4%	283,204	269,603	13,601	5.0%
<b>BENEFIX</b>	197,605	191,903	5,702	3.0%	21,615	20,893	722	3.5%	219,220	212,796	6,424	3.0%
<b>ATIVAN</b>	43,144	57,900	(14,756)	-25.5%	174,087	174,762	(675)	-0.4%	217,231	232,662	(15,431)	-6.6%
<b>SYNVISC</b>	193,688	172,890	20,798	12.0%	18,770	15,387	3,383	22.0%	212,458	188,277	24,181	12.8%
<b>REFACTO</b>	43,744	31,220	12,524	40.1%	153,805	116,039	37,766	32.5%	197,549	147,259	50,290	34.2%
<b>ENBREL</b>	-	-	-	NA	158,805	93,851	64,954	69.2%	158,805	93,851	64,954	69.2%
<b>RAPAMUNE</b>	96,602	61,231	35,371	57.8%	33,135	8,954	24,181	270.1%	129,737	70,185	59,552	84.9%
<b>MINOCIN</b>	10,798	14,584	(3,786)	-26.0%	106,326	107,543	(1,217)	-1.1%	117,124	122,127	(5,003)	-4.1%
<i>subtotal</i>	<i>6,008,864</i>	<i>5,610,046</i>	<i>398,818</i>	<i>7.1%</i>	<i>3,323,479</i>	<i>2,952,542</i>	<i>370,937</i>	<i>12.6%</i>	<i>9,332,343</i>	<i>8,562,588</i>	<i>769,755</i>	<i>9.0%</i>
<b>OTHER PHARMACEUTICALS</b>	1,051,661	1,060,207	(8,546)	-0.8%	930,479	995,118	(64,639)	-6.5%	1,982,140	2,055,325	(73,185)	-3.6%
<b>ALLIANCE REVENUE</b>	410,358	322,357	88,001	27.3%	8,420	-	8,420	NA	418,778	322,357	96,421	29.9%
<b>TOTAL WYETH PHARMACEUTICALS</b>	<b>\$ 7,470,883</b>	<b>\$ 6,992,610</b>	<b>\$ 478,273</b>	<b>6.8%</b>	<b>\$ 4,262,378</b>	<b>\$ 3,947,660</b>	<b>\$ 314,718</b>	<b>8.0%</b>	<b>\$ 11,733,261</b>	<b>\$ 10,940,270</b>	<b>\$ 792,991</b>	<b>7.2%</b>
<b>FORT DODGE</b>	301,242	378,336	(77,094)	-20.4%	352,077	397,849	(45,772)	-11.5%	653,319	776,185	(122,866)	-15.8%
<b>TOTAL PHARMACEUTICALS</b>	<b>\$ 7,772,125</b>	<b>\$ 7,370,946</b>	<b>\$ 401,179</b>	<b>5.4%</b>	<b>\$ 4,614,455</b>	<b>\$ 4,345,509</b>	<b>\$ 268,946</b>	<b>6.2%</b>	<b>\$ 12,386,580</b>	<b>\$ 11,716,455</b>	<b>\$ 670,125</b>	<b>5.7%</b>

Note: Certain reclassification adjustments have been made in 2001 in order to conform to the 2002 presentation.

**WYETH-CONSUMER HEALTH CARE**  
**WORLDWIDE NET REVENUE BY PRODUCTS**  
**TWELVE MONTHS ENDED DECEMBER 31, 2002**  
**(000's)**

	DOMESTIC				FOREIGN				TOTAL			
	YTD 2002	YTD 2001	DOLLAR CHANGE	PERCENT CHANGE	YTD 2002	YTD 2001	DOLLAR CHANGE	PERCENT CHANGE	YTD 2002	YTD 2001	DOLLAR CHANGE	PERCENT CHANGE
<b>CENTRUM</b>	\$ 353,321	\$ 335,073	\$ 18,248	5.45%	\$ 162,850	\$ 168,198	\$ (5,348)	(3.18)%	\$ 516,171	\$ 503,271	\$ 12,900	2.56%
<b>ADVIL FAMILY</b>	445,125	466,870	(21,745)	(4.66)%	109,206	95,930	13,276	13.84%	554,331	562,800	(8,469)	(1.50)%
<b>CALTRATE</b>	66,565	64,144	2,421	3.77%	75,847	84,136	(8,289)	(9.85)%	142,412	148,280	(5,868)	(3.96)%
<b>ROBITUSSIN</b>	179,964	213,688	(33,724)	(15.78)%	26,179	32,833	(6,654)	(20.27)%	206,143	246,521	(40,378)	(16.38)%
<b>SOLGAR</b>	58,952	62,976	(4,024)	(6.39)%	41,156	37,277	3,879	10.41%	100,108	100,253	(145)	(0.14)%
<b>CHAPSTICK</b>	96,339	94,198	2,141	2.27%	14,924	15,813	(889)	(5.62)%	111,263	110,011	1,252	1.14%
<b>DIMETAPP</b>	60,170	78,403	(18,233)	(23.26)%	26,668	28,123	(1,455)	(5.17)%	86,838	106,526	(19,688)	(18.48)%
<b>ALAVERT</b>	8,489	-	8,489	N/A	-	-	-	N/A	8,489	-	8,489	N/A
<b>OTHER</b>	192,767	216,948	(24,181)	(11.15)%	278,933	272,680	6,253	2.29%	471,700	489,628	(17,928)	(3.66)%
<b>TOTAL CONSUMER HEALTH CARE</b>	<b>\$ 1,461,692</b>	<b>\$ 1,532,300</b>	<b>\$ (70,608)</b>	<b>(4.61)%</b>	<b>\$ 735,763</b>	<b>\$ 734,990</b>	<b>\$ 773</b>	<b>0.11%</b>	<b>\$ 2,197,455</b>	<b>\$ 2,267,290</b>	<b>\$ (69,835)</b>	<b>(3.08)%</b>

Note: Certain reclassification adjustments have been made in 2001 in order to conform to the 2002 presentation.

**WYETH**  
**WORLDWIDE NET REVENUE BY PRODUCTS**  
**TWELVE MONTHS ENDED DECEMBER 31, 2002**  
(000's)

	DOMESTIC				FOREIGN				TOTAL			
	YTD 2002	YTD 2001	DOLLAR CHANGE	PERCENT CHANGE	YTD 2002	YTD 2001	DOLLAR CHANGE	PERCENT CHANGE	YTD 2002	YTD 2001	DOLLAR CHANGE	PERCENT CHANGE
<b>TOTAL PHARMACEUTICALS</b>	\$ 7,772,125	\$ 7,370,946	\$ 401,179	5.44%	\$ 4,614,455	\$ 4,345,509	\$ 268,946	6.19%	\$ 12,386,580	\$ 11,716,455	\$ 670,125	5.72%
<b>TOTAL CONSUMER HEALTH CARE</b>	1,461,692	1,532,300	(70,608)	(4.61)%	735,763	734,990	773	0.11%	2,197,455	2,267,290	(69,835)	(3.08)%
<b>TOTAL HEALTH CARE</b>	<b>\$ 9,233,817</b>	<b>\$ 8,903,246</b>	<b>\$ 330,571</b>	<b>3.71%</b>	<b>\$ 5,350,218</b>	<b>\$ 5,080,499</b>	<b>\$ 269,719</b>	<b>5.31%</b>	<b>\$ 14,584,035</b>	<b>\$ 13,983,745</b>	<b>\$ 600,290</b>	<b>4.29%</b>

Note: Certain reclassification adjustments have been made in 2001 in order to conform to the 2002 presentation.

**WYETH PHARMACEUTICALS**  
**WORLDWIDE NET REVENUE BY PRODUCTS**  
**4TH QUARTER 2002**  
**(000'S)**

	DOMESTIC				FOREIGN				TOTAL			
	4TH QTR 2002	4TH QTR 2001	DOLLAR CHANGE	PERCENT CHANGE	4TH QTR 2002	4TH QTR 2001	DOLLAR CHANGE	PERCENT CHANGE	4TH QTR 2002	4TH QTR 2001	DOLLAR CHANGE	PERCENT CHANGE
<b>EFFEXOR</b>	\$ 407,205	\$ 348,616	\$ 58,589	16.8%	\$ 189,670	\$ 127,214	\$ 62,456	49.1%	\$ 596,875	\$ 475,830	\$ 121,045	25.4%
<b>PREMARIN FAMILY</b>	275,102	353,422	(78,320)	-22.2%	62,442	73,724	(\$11,282)	-15.3%	337,544	427,146	(89,602)	-21.0%
<b>PROTONIX</b>	286,976	107,268	179,708	167.5%	-	-	-	NA	286,976	107,268	179,708	167.5%
<b>NUTRITIONALS</b>	16,749	13,448	3,301	24.5%	210,849	189,208	21,641	11.4%	227,598	202,656	24,942	12.3%
<b>ORAL CONTRACEPTIVES</b>	31,522	86,271	(54,749)	-63.5%	101,912	103,714	(1,802)	-1.7%	133,434	189,985	(56,551)	-29.8%
<b>PREVNAR</b>	211,416	208,965	2,451	1.2%	23,198	16,823	6,375	37.9%	234,614	225,788	8,826	3.9%
<b>CORDARONE</b>	(15,414)	73,463	(88,877)	-121.0%	850	715	135	18.9%	(14,564)	74,178	(88,742)	-119.6%
<b>ZOSYN/TAZOCIN</b>	69,069	63,373	5,696	9.0%	60,696	52,244	8,452	16.2%	129,765	115,617	14,148	12.2%
<b>ZOTON</b>	-	-	-	NA	85,033	77,358	7,675	9.9%	85,033	77,358	7,675	9.9%
<b>SYNVISC</b>	40,138	40,217	(79)	-0.2%	5,096	4,043	1,053	26.0%	45,234	44,260	974	2.2%
<b>BENEFIX</b>	51,004	43,016	7,988	18.6%	7,019	4,839	2,180	45.1%	58,023	47,855	10,168	21.2%
<b>ATIVAN</b>	14,754	18,165	(3,411)	-18.8%	48,864	45,808	3,056	6.7%	63,618	63,973	(355)	-0.6%
<b>REFACTO</b>	12,932	7,318	5,614	76.7%	40,983	29,889	11,094	37.1%	53,915	37,207	16,708	44.9%
<b>ENBREL</b>	-	-	-	NA	46,394	30,812	15,582	50.6%	46,394	30,812	15,582	50.6%
<b>MINOCIN</b>	3,860	5,590	(1,730)	-30.9%	30,095	28,871	1,224	4.2%	33,955	34,461	(506)	-1.5%
<b>RAPAMUNE</b>	33,599	17,280	16,319	94.4%	11,008	4,059	6,949	171.2%	44,607	21,339	23,268	109.0%
<i>subtotal</i>	<i>1,438,912</i>	<i>1,386,412</i>	<i>52,500</i>	<i>3.8%</i>	<i>924,109</i>	<i>789,321</i>	<i>134,788</i>	<i>17.1%</i>	<i>2,363,021</i>	<i>2,175,733</i>	<i>187,288</i>	<i>8.6%</i>
<b>OTHER PHARMACEUTICALS</b>	299,364	268,834	30,530	11.4%	240,692	253,118	(12,426)	-4.9%	540,056	521,952	18,104	3.5%
<b>ALLIANCE REVENUE</b>	123,210	118,782	4,428	3.7%	6,938	-	6,938	NA	130,148	118,782	11,366	9.6%
<b>TOTAL WYETH PHARMACEUTICALS</b>	<b>\$ 1,861,486</b>	<b>\$ 1,774,028</b>	<b>\$ 87,458</b>	<b>4.9%</b>	<b>\$ 1,171,739</b>	<b>\$ 1,042,439</b>	<b>\$ 129,300</b>	<b>12.4%</b>	<b>\$ 3,033,225</b>	<b>\$ 2,816,467</b>	<b>\$ 216,758</b>	<b>7.7%</b>
<b>FORT DODGE</b>	82,115	110,643	(28,528)	-25.8%	87,428	105,929	(18,501)	-17.5%	169,543	216,572	(47,029)	-21.7%
<b>TOTAL PHARMACEUTICALS</b>	<b>\$ 1,943,601</b>	<b>\$ 1,884,671</b>	<b>\$ 58,930</b>	<b>3.1%</b>	<b>\$ 1,259,167</b>	<b>\$ 1,148,368</b>	<b>\$ 110,799</b>	<b>9.6%</b>	<b>\$ 3,202,768</b>	<b>\$ 3,033,039</b>	<b>\$ 169,729</b>	<b>5.6%</b>

Note: Certain reclassification adjustments have been made in 2001 in order to conform to the 2002 presentation.

**WYETH-CONSUMER HEALTH CARE**  
**WORLDWIDE NET REVENUE BY PRODUCTS**  
**4TH QUARTER 2002**  
**(000's)**

	DOMESTIC				FOREIGN				TOTAL			
	4TH QTR 2002	4TH QTR 2001	DOLLAR CHANGE	PERCENT CHANGE	4TH QTR 2002	4TH QTR 2001	DOLLAR CHANGE	PERCENT CHANGE	4TH QTR 2002	4TH QTR 2001	DOLLAR CHANGE	PERCENT CHANGE
<b>CENTRUM</b>	\$ 85,657	\$ 84,117	\$ 1,540	1.83%	\$ 45,136	\$ 46,933	\$ (1,797)	(3.83)%	\$ 130,793	\$ 131,050	\$ (257)	(0.20)%
<b>ADVIL FAMILY</b>	119,439	134,936	(15,497)	(11.48)%	30,659	26,573	4,086	15.38%	150,098	161,509	(11,411)	(7.07)%
<b>CALTRATE</b>	17,939	17,194	745	4.33%	24,017	26,067	(2,050)	(7.86)%	41,956	43,261	(1,305)	(3.02)%
<b>ROBITUSSIN</b>	63,094	75,566	(12,472)	(16.50)%	4,406	5,921	(1,515)	(25.59)%	67,500	81,487	(13,987)	(17.16)%
<b>SOLGAR</b>	12,625	12,986	(361)	(2.78)%	9,712	7,305	2,407	32.95%	22,337	20,291	2,046	10.08%
<b>CHAPSTICK</b>	39,431	33,016	6,415	19.43%	4,660	6,985	(2,325)	(33.29)%	44,091	40,001	4,090	10.22%
<b>DIMETAPP</b>	19,449	21,673	(2,224)	(10.26)%	13,382	18,009	(4,627)	(25.69)%	32,831	39,682	(6,851)	(17.26)%
<b>ALAVERT</b>	8,489	-	8,489	N/A	-	-	-	N/A	8,489	-	8,489	N/A
<b>OTHER</b>	43,427	60,293	(16,866)	(27.97)%	69,704	72,855	(3,151)	(4.33)%	113,131	133,148	(20,017)	(15.03)%
<b>TOTAL CONSUMER HEALTH CARE</b>	<b>\$ 409,550</b>	<b>\$ 439,781</b>	<b>\$ (30,231)</b>	<b>(6.87)%</b>	<b>\$ 201,676</b>	<b>\$ 210,648</b>	<b>\$ (8,972)</b>	<b>(4.26)%</b>	<b>\$ 611,226</b>	<b>\$ 650,429</b>	<b>\$ (39,203)</b>	<b>(6.03)%</b>

Note: Certain reclassification adjustments have been made in 2001 in order to conform to the 2002 presentation.

**WYETH**  
**WORLDWIDE NET REVENUE BY PRODUCTS**  
**4TH QUARTER 2002**  
**(000's)**

	DOMESTIC				FOREIGN				TOTAL			
	4TH QTR 2002	4TH QTR 2001	DOLLAR CHANGE	PERCENT CHANGE	4TH QTR 2002	4TH QTR 2001	DOLLAR CHANGE	PERCENT CHANGE	4TH QTR 2002	4TH QTR 2001	DOLLAR CHANGE	PERCENT CHANGE
<b>TOTAL PHARMACEUTICALS</b>	\$ 1,943,601	\$ 1,884,671	\$ 58,930	3.13%	\$ 1,259,167	\$ 1,148,368	\$ 110,799	9.65%	\$ 3,202,768	\$ 3,033,039	\$ 169,729	5.60%
<b>TOTAL CONSUMER HEALTH CARE</b>	409,550	439,781	(30,231)	(6.87)%	201,676	210,648	(8,972)	(4.26)%	611,226	650,429	(39,203)	(6.03)%
<b><i>TOTAL HEALTH CARE</i></b>	<b>\$ 2,353,151</b>	<b>\$ 2,324,452</b>	<b>\$ 28,699</b>	<b>1.23%</b>	<b>\$ 1,460,843</b>	<b>\$ 1,359,016</b>	<b>\$ 101,827</b>	<b>7.49%</b>	<b>\$ 3,813,994</b>	<b>\$ 3,683,468</b>	<b>\$ 130,526</b>	<b>3.54%</b>

Note: Certain reclassification adjustments have been made in 2001 in order to conform to the 2002 presentation.

**WYETH-PHARMACEUTICALS  
PREMARIN FAMILY  
NET REVENUE**

	4TH QUARTER				2002 % of Total	12 MONTHS ENDED				2002 % of Total
	2002	2001	\$ Chg	% Chg		2002	2001	\$ Chg	% Chg	
<b><u>Domestic:</u></b>										
Premarin	\$ 207,674	\$ 203,260	\$ 4,414	2.2%	75.5%	\$ 1,104,835	\$ 1,045,898	\$ 58,937	5.6%	68.5%
Prempro/phase	67,428	150,162	(82,734)	-55.1%	24.5%	509,007	749,660	(240,653)	-32.1%	31.5%
Premarin Family	275,102	353,422	(78,320)	-22.2%	100.0%	1,613,842	1,795,558	(181,716)	-10.1%	100.0%
<b><u>Foreign:</u></b>										
Premarin	33,873	36,800	(2,927)	-8.0%	54.2%	138,322	139,742	(1,420)	-1.0%	52.0%
Prempro/phase	28,569	36,924	(8,355)	-22.6%	45.8%	127,696	138,225	(10,529)	-7.6%	48.0%
Premarin Family	62,442	73,724	(11,282)	-15.3%	100.0%	266,018	277,967	(11,949)	-4.3%	100.0%
<b><u>Total:</u></b>										
Premarin	241,547	240,060	1,487	0.6%	71.6%	1,243,157	1,185,640	57,517	4.9%	66.1%
Prempro/phase	95,997	187,086	(91,089)	-48.7%	28.4%	636,703	887,885	(251,182)	-28.3%	33.9%
Premarin Family	\$ 337,544	\$ 427,146	\$ (89,602)	-21.0%	100.0%	\$ 1,879,860	\$ 2,073,525	\$ (193,665)	-9.3%	100.0%

	12 MONTHS ENDED				2001 % of Total
	2001	2000	\$ Chg	% Chg	
<b><u>Domestic:</u></b>					
Premarin	\$ 1,045,898	\$ 912,157	\$ 133,741	14.7%	58.2%
Prempro/phase	749,660	686,259	63,401	9.2%	41.8%
Premarin Family	1,795,558	1,598,416	197,142	12.3%	100.0%
<b><u>Foreign:</u></b>					
Premarin	139,742	141,856	(2,114)	-1.5%	50.3%
Prempro/phase	138,225	129,949	8,276	6.4%	49.7%
Premarin Family	277,967	271,805	6,162	2.3%	100.0%
<b><u>Total:</u></b>					
Premarin	1,185,640	1,054,013	131,627	12.5%	57.2%
Prempro/phase	887,885	816,208	71,677	8.8%	42.8%
Premarin Family	\$ 2,073,525	\$ 1,870,221	\$ 203,304	10.9%	100.0%